cost-effectiveness

How Can the U.S. Healthcare System Better Measure Cost-Effectiveness?

The recent and frequent outcry over expensive drugs has made evident the gap in the United States’ healthcare system. While no perfect system exists, other countries have health technology assessment (HTA) agencies to evaluate efficacy and/or cost-effectiveness and inform reimbursement decisions.

What might the U.S. learn from countries like England, Germany, and France in structuring a methodology for evaluating drugs?

ASCO Conceptual Value Framework Demonstrates Gap in US Healthcare Valuation Process

The ongoing debate around the high cost of drugs in the United States, especially in oncology, has produced interesting responses from special interest groups. The American Society for Clinical Oncology (ASCO) is the latest to enter the fray, believing they may have found a solution for drug valuation in the United States. Does ASCO’s new framework solve a problem in the drug evaluation process in the United States, or does it expose a serious and still unmet need?